AR076968A1 - Compuestos de 1h-imidazo-(4,5-c)-quinolinona - Google Patents

Compuestos de 1h-imidazo-(4,5-c)-quinolinona

Info

Publication number
AR076968A1
AR076968A1 ARP100101965A ARP100101965A AR076968A1 AR 076968 A1 AR076968 A1 AR 076968A1 AR P100101965 A ARP100101965 A AR P100101965A AR P100101965 A ARP100101965 A AR P100101965A AR 076968 A1 AR076968 A1 AR 076968A1
Authority
AR
Argentina
Prior art keywords
pyridyl
alkyl
alkoxy
amino
substituted
Prior art date
Application number
ARP100101965A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR076968A1 publication Critical patent/AR076968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere al uso de compuestos de 1H-imidazo-[4,5-c]-quinolinona y sales de los mismos en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido, y a la elaboracion de preparaciones farmacéuticas para el tratamiento de estas enfermedades; a compuestos de 1H-imidazo-[4,5-c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de cinasa de proteína y/o de lípido; a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los compuestos de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, en especial, a un ser humano; a las preparaciones farmacéuticas que comprenden un compuesto de 1H-imidazo-[4,5-c]- quinolinona, en especial, para el tratamiento de una enfermedad dependiente de cinasa de proteína y/o de lípido; a compuestos novedosos de 1H-imidazo-[4,5- c]-quinolinona; y a un proceso para la preparacion de los compuestos novedosos de 1 H-imidazo-[4,5-c]-quinolinona. Reivindicacion 1: Un compuesto de la formula (1) en donde X es O o S; Y es CH o N; R1 es piridilo sustituido o insustituido; R2 es hidrogeno o alquilo inferior; R3 es un arilo sustituido o insustituido, o heterociclilo; y R4, R5 y R6 son hidrogeno; o una sal farmacéuticamente aceptable del mismo. Reivindicacion 2: Un compuesto de acuerdo con la reivindicacion 1 en donde: R1 es piridilo que está insustituido o independientemente sustituido por uno, dos o tres sustituyentes seleccionados a partir de halogeno, alquilo insustituido o sustituido, alquenilo insustituido o sustituido, alquinilo insustituido o sustituido, alcoxilo inferior insustituido o sustituido, alcoxi-alquilo inferior insustituido o sustituido, alcoxilo inferior-alcoxilo inferior insustituido o sustituido, cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido, carbamoil-alquilo inferior insustituido o sustituido, mono y di-alquilo inferior-carbamoil-alquilo inferior, cicloamino-carbonilalquilo inferior insustituido o sustituido, heterociclil-carbonil-alquilo inferior insustituido o sustituido, hidroxi-alquilo inferior insustituido o sustituido, carboxi-alquilo inferior insustituido o sustituido, halo-alquilo inferior, hidroxi-carbonil-alquilo inferior, pirazinilo insustituido o sustituido, hidroxilo, amino, amino sustituido por mono- o di-alquilo inferior, piperazinilo insustituido o sustituido, amino sustituido por N-alquilo inferior-N-alcoxilo inferior-alquilo inferior, alcoxilo inferior-alquilo inferior-carbonil-amino, oxopiperazinilo, cicloamino insustituido o sustituido, amino sustituido por N-alquilo inferior-N-hidroxi-alquilo inferior o una sal farmacéuticamente aceptable del mismo. Reivindicacion 6: Un compuesto de acuerdo con cualquiera de las reivindicaciones anteriores, en donde R3 se selecciona a partir de fenilo; hidroxi-fenilo; metoxifenilo; etoxi-fenilo; metoxi-etoxi-fenilo; metoxi-(metoxi-etoxi)-fenilo, hidroxi-alcoxi-fenilo; halo-hidroxi-fenilo; hidroxi-halo-alquil-fenilo; 2,2-difluoro-benzo-[1,3]-dioxolo; bencen-sulfonamida; 3-(pirrolidin-1-sulfonil)-fenilo; N-(fen-3-il)-metan-sulfonamida; N-metil-N-fen-3-il- metan-sulfonamida; alquil-sulfonil-fenilo; benzamida; N-metil-benzamida; N,N-dimetil-benzamida; pirazol-fenilo; imidazol-fenilo; piridilo; alquil-piridilo; alcoxi-piridilo; etoxi-piridilo; propoxi-piridilo; cicloalquil-alcoxi-piridilo; alcoxi-alquil-piridilo; alcoxi-alcoxi-piridilo; benciloxi-alcoxi-piridilo; hidroxi-alquil-piridilo; alquil-sulfonil-piridilo; hidroxi-alcoxi-piridilo; alcoxi-carbonil-piridilo; amino-piridilo; alquilamino-piridilo; dialquil-amino-piridilo; cicloamino-piridilo; (cianoalquilo inferior)-piridinilo; (ciano-cicloalquilo inferior)-piridinilo; hidroxi-alquilo-amino-piridilo; amino-halo-alquilo inferior-piridilo; halo-alquil-piridinilo; halo-piridilo; halo-alcoxi-piridilo; carbamoil-piridilo; carbamoilo sustituido por alquilo; piperazinil-piridilo; N-alquil-piperazinil-piridilo; alquil-sulfonamido-piridilo; dialquil-sulfonamido-piridilo; (alquil-sulfonamido)-(alquil)-piridilo; dialquil-sulfonamido-(alquil)-piridilo; 3H-tetrazol-5-il-piridilo; (alcoxi)-(alquil-carbonil-amino)-piridilo; (alcoxi)-(alquil-carbonil-N-alquil-amino)-piridilo; (alcoxi)-(nitro)-piridilo; (alcoxi)-(amino)-piridilo; (alcoxi)-(alquil-amino-carbonil)-piridilo; (alcoxi)-(hidroxi-carbonil)-piridilo; N,N-di-alquilo inferior-amino-alcoxilo inferior; (N,N-dimetil-amino-propoxi)-piridilo; (alquil)-(alcoxi)-piridilo; (dialcoxi-alquil)-(alcoxi)-piridilo; (alcoxi-alquil)-(alcoxi )-piridilo; (hidroxi-alquil)-alquil-amino)-piridilo; (alquil)-(alquil-amino)-piridilo; (habo)-(alquil-amino)-piridilo; (halo-alquil)-(alquil-amino)-piridilo; (habo-alquil)-(amino)-piridilo; (hidroxi-alquil)-(alcoxi)-piridilo; (hidroxi-alquil)-(amino)-piridilo; (alcoxi-alquil)-(amino)-piridilo; (alquil)-(alcoxi-alcoxi)-piridilo; (alcoxi-alquil)-(alquil-amino)-piridilo; (amino)-(alquil-amino-carbonil)-piridilo; pirimidinilo; alquilo inferior-amino-pirimidinilo; di-alquilo Inferior-amino-pirimidinilo; alcoxi-pirimidinilo; di-alcoxilo inferior-pirimidinilo; (alquil-amino)-(alcoxi)-pirimidinilo; 1H-pirrolo-[2,3-b]-piridinilo; 1-metil-1H-pirrolo-[2,3-b]-piridinilo; pirazinilo; pirazolilo; pirazolilo sustituido; quinolinilo; 2-oxo-2,3-dihidro-1H-indol-5-ilo; 1-metil-2,3-dihidro-1H-indol-5-ilo; 1H-imidazo-[4,5-b]-piridin-2(3H)-on-6-ilo; 3H-imidazo-[4,5-b]-piridin-6-ilo; 3H-[1,2,3]-triazolo-[4,5-b]-piridin-6-ilo; imidazo-[1,2-a]-piridinilo, o una sal farmacéuticamente aceptable del mismo.
ARP100101965A 2009-06-04 2010-06-03 Compuestos de 1h-imidazo-(4,5-c)-quinolinona AR076968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21783609P 2009-06-04 2009-06-04

Publications (1)

Publication Number Publication Date
AR076968A1 true AR076968A1 (es) 2011-07-20

Family

ID=42670520

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101965A AR076968A1 (es) 2009-06-04 2010-06-03 Compuestos de 1h-imidazo-(4,5-c)-quinolinona

Country Status (8)

Country Link
US (1) US20100311714A1 (es)
EP (1) EP2438063A1 (es)
JP (1) JP2012528829A (es)
CN (1) CN102803259A (es)
AR (1) AR076968A1 (es)
TW (1) TW201100420A (es)
UY (1) UY32691A (es)
WO (1) WO2010139747A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012008049A (es) * 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
EP2648733A1 (en) 2010-12-06 2013-10-16 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013016411A1 (en) * 2011-07-28 2013-01-31 Garry Robert Smith Novel fluorinated cyclic sulfamides exhibiting neuroprotective action and their method of use
CN103030637A (zh) * 2011-10-10 2013-04-10 上海恒瑞医药有限公司 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
NO2714752T3 (es) 2014-05-08 2018-04-21
SI3560924T1 (sl) 2015-04-02 2021-08-31 Merck Patent Gmbh Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519406D0 (en) * 2015-11-03 2015-12-16 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB201604182D0 (en) * 2016-03-11 2016-04-27 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
BR112019007594A2 (pt) 2016-10-13 2019-07-02 Loyola University Of Chicago método para bloquear a transmissão do parasita da malária
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
EP4034094A4 (en) * 2019-09-23 2024-01-24 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. PHOSPHODIESTERASE INHIBITORS AND THEIR USE
US20230014730A1 (en) 2019-09-23 2023-01-19 Nanjing Zhengxiang Pharmaceuticals Co., Ltd. Phosphodiesterase inhibitors and use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20090082387A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
UY32691A (es) 2011-01-31
TW201100420A (en) 2011-01-01
US20100311714A1 (en) 2010-12-09
CN102803259A (zh) 2012-11-28
EP2438063A1 (en) 2012-04-11
JP2012528829A (ja) 2012-11-15
WO2010139747A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
AR076968A1 (es) Compuestos de 1h-imidazo-(4,5-c)-quinolinona
CA2908776C (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
RU2519673C2 (ru) Комбинации ингибитора hsp90
US9902727B2 (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
US10202385B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinazolines
CA3045465A1 (en) Preservation of immune response during chemotherapy regimens
ES2873959T3 (es) Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer
WO2015157125A1 (en) Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
ES2639402T3 (es) 2,3-dihidroimidazo[1,2-c]quinolinas sustituidas con arilaminoalcohol
PE20141023A1 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
CA2978807A1 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US11878972B2 (en) Treatment of neurological disorders
AU2017208948A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
NZ712033B2 (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Legal Events

Date Code Title Description
FB Suspension of granting procedure